<DOC>
	<DOCNO>NCT02738905</DOCNO>
	<brief_summary>The purpose study determine rifaximin reduces serum trimethylamine-N-oxide ( TMAO ) level patient end-stage renal disease .</brief_summary>
	<brief_title>Impact Rifaximin Therapy Intestinal Byproducts End-Stage Renal Disease</brief_title>
	<detailed_description>Study participant undergo 3 study visit : baseline , day 7 ( immediately post-therapy ) , day 21 ( 2 week post-therapy ) . All participant provide blood stool sample visit .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Diagnosis endstage renal disease Receiving chronic intermittent hemodialysis Patients less advanced kidney disease Inability unwillingness provide inform consent Patients may pregnant Hemodynamically unstable patient Patients liver failure , pancreatic insufficiency , inflammatory bowel disease Patients ongoing recent infection history Cdiff infection Patients abnormal bowel structure secondary surgical anatomic variation Patients certain medication , include immunosuppressant , antidiarrheal agent , recent ( within last 2 month ) use antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>